Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection

BACKGROUND: Once-daily, orally administered, co-formulated glecaprevir (NS3/4A protease inhibitor) and pibrentasvir (NS5A inhibitor) (G/P) demonstrated pangenotypic activity and high sustained virologic response (SVR) rates in studies outside Japan. Here we report safety and efficacy in a subset of...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Gastroenterol
Autors principals: Kumada, Hiromitsu, Watanabe, Tsunamasa, Suzuki, Fumitaka, Ikeda, Kenji, Sato, Ken, Toyoda, Hidenori, Atsukawa, Masanori, Ido, Akio, Takaki, Akinobu, Enomoto, Nobuyuki, Kato, Koji, Alves, Katia, Burroughs, Margaret, Redman, Rebecca, Pugatch, David, Pilot-Matias, Tami J., Krishnan, Preethi, Oberoi, Rajneet K., Xie, Wangang, Chayama, Kazuaki
Format: Artigo
Idioma:Inglês
Publicat: Springer Japan 2017
Matèries:
Original Article—Liver, Pancreas, and Biliary Tract
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5866827/
https://ncbi.nlm.nih.gov/pubmed/29052790
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00535-017-1396-0
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars